The Current State of Biological and Clinical Implications of Human Papillomavirus-Related Oropharyngeal Cancer

In the effort to control human papillomavirus-related oropharyngeal cancer, the head and neck oncology community has devoted much effort to understanding its disease biology and clinical behavior, and refining strategies to address early diagnosis and optimal management for the affected population. This review identifies articles published up to March 2017 on tumor biology and clinical implications of human papillomavirus-related oropharyngeal cancer, and summarizes the findings in some key areas.
Source: Seminars in Radiation Oncology - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

To the Editor We read with interest the report by Masroor et al, suggesting that among patients with human papillomavirus (HPV)-associated oropharyngeal cancers, National Comprehensive Cancer Network (NCCN)-recommended regular posttreatment clinical examinations did not detect recurrence or improve survival, compared with observation. Among the 22 of 233 study patients who had recurrent disease, the authors report that 10 were symptom directed and 11 were imaging detected, indicating that half of all recurrences were detected by imaging, which contradicts the NCCN ’s statement that most recurrences are reported by th...
Source: JAMA Otolaryngology - Head and Neck Surgery - Category: ENT & OMF Source Type: research
MONDAY, Jan. 13, 2020 -- For patients with oropharynx cancer, the rates of head and neck cancer (HNC) mortality and competing mortality vary depending on human papillomavirus (HPV) status, with increased risks for HNC mortality and competing...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
ConclusionThe majority of MDT decisions followed guidelines and any discordant decisions were justifiable. Discussing management options with patients beforehand facilitates decision implementation as decisions can potentially change after seeing the patient. Progress is still needed with regards to HPV testing. Reasons for not testing could include subliminal decision-making among clinicians, and patients falling between centres. Crucially, the role of the MDT in head and neck cancer should be to ratify decisions rather than making them, hence the need to see patients prior to MDT discussion.
Source: European Archives of Oto-Rhino-Laryngology - Category: ENT & OMF Source Type: research
Increasing evidence indicates an etiological role of human papillomavirus (HPV) in head and neck cancers, particularly oropharyngeal squamous cell carcinoma (OPSCC). However, the association between HPV and ot...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Authors: Durkova J, Boldis M, Kovacova S Abstract Over the course of the last two decades, there has been a decrease in the incidence of head and neck cancers thanks to a decreasing prevalence of smoking. However, a new risk factor has been coming to the fore: human papillomavirus infection (HPV). HPV-positive oropharyngeal squamous cell carcinoma (HPV+OPC) is more sensitive to chemotherapy and radiotherapy, which translates to a much better prognosis with conventional treatment protocols than tumours that are HPV-negative. Traditional therapeutic interventions are associated with substantial morbidity and have a g...
Source: Biomedical Papers of the Medical Faculty of the Univ Palacky Olomouc Czech Repub - Category: Biomedical Science Tags: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Source Type: research
Authors: Tribius S, Würdemann N, Laban S, Hoffmann TK, Sharma SJ, Klussmann JP Abstract At this year's Annual Meeting of the American Society for Clinical Oncology (ASCO), the keyword search "HPV-associated head and neck cancer" resulted in 920 hits-74% of the hits on human papillomavirus (HPV). This underlines the relevance of the topic. The spectrum ranged from validation and separation of the prognostic groups of patients with HPV-associated oropharyngeal carcinoma (OPSCC) according to TNM 8, to the characterization of new tumor markers and tumor mutational burden for possible de-escalation s...
Source: HNO - Category: ENT & OMF Tags: HNO Source Type: research
n Human papillomavirus (HPV) infection is the cause of a growing percentage of head and neck cancers (HNC); primarily, a subset of oral squamous cell carcinoma, oropharyngeal squamous cell carcinoma, and laryngeal squamous cell carcinoma. The majority of HPV-associated head and neck cancers (HPV + HNC) are caused by HPV16; additionally, co-factors such as smoking and immunosuppression contribute to the progression of HPV + HNC by interfering with tumor suppressor miRNA and impairing mediators of the immune system. This review summarizes current studies on HPV + HNC, ranging from potential modes of oral transmission of ...
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research
In this issue of JAMA Otolaryngology –Head&Neck Surgery, Masroor at al explore the outcomes associated with adherence to the current National Comprehensive Cancer Network (NCCN) posttreatment surveillance recommendations for patients with human papillomavirus –associated oropharyngeal squamous cell carcinoma (HPV-associated OPSCC). Recognition of the favorable prognosis of HPV-associated OPSCC has led to the issue of whether the current NCCN-guided surveillance recommendations are appropriate for survivors of HPV-associated OPSCC. The goals of a regula r surveillance schedule are to identify cancer recurren...
Source: JAMA Otolaryngology - Head and Neck Surgery - Category: ENT & OMF Source Type: research
We read with great interest the Oncology Scan article by Anderson et  al.1 The paper focused on the latest findings indicating that radiation therapy plus cetuximab led to inferior overall survival in human papillomavirus (HPV)–positive patients with oropharyngeal cancer (OPC), compared with standard concurrent platinum-based chemotherapy. The authors summarize an d comment on the recent results of 2 large prospective randomized trials2,3 published in January 2019 in The Lancet. Both trials were based on the hypothesis that substituting cisplatin with cetuximab could offer a valid, but less toxic, alternative as...
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Comment Source Type: research
Conclusion: PDX from OPSCC preserves important molecular characteristics of the human primary tumor. Radiosensitivity were in accordance with clinically observed treatment response. The PDX model is a clinically relevant surrogate model of head and neck cancer. Perspectives include increased understanding of disease biology, which could lead to development of novel treatments and biomarkers. PMID: 31510843 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Genital Warts | Head and Neck Cancer | Human Papillomavirus (HPV) | Oropharyngeal Cancer